Immunotherapeutics for Ebola Virus Disease: Hope on the Horizon

References

• Kuhn JH, Amarasinghe GK, Basler CF, et al. ICTV Virus taxonomy profile: filoviridae. J Gen Virol. 2019;100(6):911–912. doi:10.1099/jgv.0.001252
   Web of Science ®Google Scholar
• Bell BP, Damon IK, Jernigan DB, et al. Overview, control strategies, and lessons learned in the CDC response to the 2014–2016 Ebola Epidemic. Morbidity Mortality Weekly Rep. 2016;1(65):4–11.
   Google Scholar
• World Health Organization. Ebola virus disease Democratic Republic of Congo: external situation report 98/ 2020; 2020. Available from: https://www.who.int/publications/i/item/10665-332654.Accessed November 18, 2020.
   Google Scholar
• World Health Organization. Regional Office for Africa. Ebola Virus Dis. 2019.
   Google Scholar
• Center for Disease Control and Prevention. 2020 Democratic Republic of the Congo, Equateur province; 2020. CDC. Available from: https://www.cdc.gov/vhf/ebola/outbreaks/drc/2020-june.html. Accessed December 6, 2020.
   Google Scholar
• Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–862. doi:10.1016/S0140-6736(10)60667-8
   PubMed Web of Science ®Google Scholar
• Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204(Suppl 3):S810–S816. doi:10.1093/infdis/jir299
   PubMed Web of Science ®Google Scholar
• Fowler RA, Fletcher T, Fischer WA 2nd, et al. Caring for critically ill patients with ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190(7):733–737. doi:10.1164/rccm.201408-1514CP
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1.
   PubMed Web of Science ®Google Scholar
• Wheeler TT, Hodgkinson AJ, Prosser CG, Davis SR. Immune components of colostrum and milk – a historical perspective. J Mammary Gland Biol Neoplasia. 2007;12(4):237–247. doi:10.1007/s10911-007-9051-7
   PubMed Web of Science ®Google Scholar
• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(23):1073–1078. doi:10.1038/nbt0905-1073
   Web of Science ®Google Scholar
• Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs. 2007;21(1):1–7. doi:10.2165/00063030-200721010-00001
   Web of Science ®Google Scholar
• Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179(Suppl 1):S18–S23. doi:10.1086/514298
   PubMed Web of Science ®Google Scholar
• Kudoyarova-Zubavichene NMSN, Chepurnov AA, Netesov SV. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections. J Infect Dis. 1999;179:218–223. doi:10.1086/514294
   PubMed Web of Science ®Google Scholar
• Jahrling PB. Passive Immunization of Ebola Virus-Infected Cynomolgus Monkeys with Immunoglobulin from Hyperimmune Horses. Vol. 11. Vienna: Springer; 1996.
   Google Scholar
• Wang H, Wong G, Zhu W, et al. Equine-origin immunoglobulin fragments protect nonhuman primates from ebola virus disease. J Virol. 2019;93(5):e01548–e01518. doi:10.1128/JVI.01548-18
   PubMed Web of Science ®Google Scholar
• Maruyama T, Rodrifuez LL, Jahrling PB, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999;73(7):6024–6030. doi:10.1128/JVI.73.7.6024-6030.1999
   PubMed Web of Science ®Google Scholar
• Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol. 2002;76(12):6408–6412. doi:10.1128/JVI.76.12.6408-6412.2002
   PubMed Web of Science ®Google Scholar
• Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 2007;3(1):e9. doi:10.1371/journal.ppat.0030009
   PubMed Web of Science ®Google Scholar
• Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A. 2012;109(13):5034–5039. doi:10.1073/pnas.1200409109
   PubMed Web of Science ®Google Scholar
• Marzi A, Yoshida R, Miyamoto H, et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One. 2012;7(4):e36192. doi:10.1371/journal.pone.0036192
   PubMed Web of Science ®Google Scholar
• Qiu X, Audet J, Wong G, et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med. 2012;4(138):138ra181. doi:10.1126/scitranslmed.3003876
   Web of Science ®Google Scholar
• Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A. 2012;109(44):18030–18035. doi:10.1073/pnas.1213709109
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Pettitt J, Scully C, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A. 2011;108(51):20690–20694. doi:10.1073/pnas.1108360108
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. doi:10.3389/fimmu.2019.01296
   PubMed Web of Science ®Google Scholar
• Liu Q, Fan C, Li Q, et al. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci Rep. 2017;7(1):45552. doi:10.1038/srep45552
   Web of Science ®Google Scholar
• Pettitt J, Zeitlin L, Kim Do H, et al. Therapeutic Intervention of Ebola virus infection in rhesus macaques with the MB-003 Monoclonal Antibody Cocktail. Sci Transl Med. 2013;5(199):199ra113. doi:10.1126/scitranslmed.3006608
   PubMed Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47–53. doi:10.1038/nature13777
   PubMed Web of Science ®Google Scholar
• Misasi J, Gilman MS, Kanekiyo M, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016;351(6279):1343–1346. doi:10.1126/science.aad6117
   PubMed Web of Science ®Google Scholar
• Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351(6279):1339–1342. doi:10.1126/science.aad5224
   PubMed Web of Science ®Google Scholar
• Pascal KE, Dudgeon D, Trefry JC, et al. Development of clinical-stage human monoclonal antibodies that treat advanced ebola virus disease in nonhuman primates. J Infect Dis. 2018;218(suppl_5):S612–S626. doi:10.1093/infdis/jiy285
   PubMed Web of Science ®Google Scholar
• Markham A. REGN-EB3: first approval. Drugs. 2021;81(1):175–178. doi:10.1007/s40265-020-01452-3
   Web of Science ®Google Scholar
• Wec AZ, Bornholdt ZA, He S, et al. Development of a human antibody cocktail that deploys multiple functions to confer pan-ebolavirus protection. Cell Host Microbe. 2019;25(1):39–48 e35. doi:10.1016/j.chom.2018.12.004
   PubMed Web of Science ®Google Scholar
• Bornholdt ZA, Herbert AS, Mire CE, et al. A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates. Cell Host Microbe. 2019;25(1):49–58 e45. doi:10.1016/j.chom.2018.12.005
   PubMed Web of Science ®Google Scholar
• Wec AZ, Nyakatura EK, Herbert AS, et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354(6310):350–354. doi:10.1126/science.aag3267
   PubMed Web of Science ®Google Scholar
• Davey RT Jr; PREVAIL II Writing Group, Multi-National PTEVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola Virus Infection. N Engl J Med. 2016;375(15):1448–1456.
   Web of Science ®Google Scholar
• Gaudinski MR, Coates EE, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019;393(10174):889–898. doi:10.1016/S0140-6736(19)30036-4
   PubMed Web of Science ®Google Scholar
• Sivapalasingam S, Kamal M, Slim R, et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. Lancet Infect Dis. 2018;18(8):884–893. doi:10.1016/S1473-3099(18)30397-9
   Web of Science ®Google Scholar
• Ottoni MP, Ricciardone JD, Nadimpalli A, et al. Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series. Lancet Child Adolescent Health. 2020;4(12):884–888. doi:10.1016/S2352-4642(20)30278-9
   Google Scholar
• Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola Virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303. doi:10.1056/NEJMoa1910993
   PubMed Web of Science ®Google Scholar
• Regeneron. Regeneron’s antibody cocktail REGN-EB3 is first FDA-approved treatment for Ebola; 2020. Available from: https://investor.regeneron.com/news-releases/news-release-details/regenerons-antibody-cocktail-regn-eb3-inmazebr-first-fda. Accessed March 5, 2021.
   Google Scholar
• Wang BX, Fish EN. The yin and yang of viruses and interferons. Trends Immunol. 2012;33(4):190–197. doi:10.1016/j.it.2012.01.004
   Web of Science ®Google Scholar
• Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015;13(11):663–676. doi:10.1038/nrmicro3524
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental ebola virus infections. J Infect Dis. 1999;179(179):S224–S234. doi:10.1086/514310
   Web of Science ®Google Scholar
• Smith LM, Hensley LE, Geisbert TW, et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis. 2013;208(2):310–318. doi:10.1093/infdis/jis921
   PubMed Web of Science ®Google Scholar
• McCarthy SD, Majchrzak-Kita B, Racine T, et al. A rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of Ebola Virus. PLoS Negl Trop Dis. 2016;10(1):e0004364. doi:10.1371/journal.pntd.0004364
   Web of Science ®Google Scholar
• Konde MK, Baker DP, Traore FA, et al. Interferon beta-1a for the treatment of Ebola virus disease: a historically controlled, single-arm proof-of-concept trial. PLoS One. 2017;12(2):e0169255. doi:10.1371/journal.pone.0169255
   PubMed Web of Science ®Google Scholar
• Kondratowicz AS, Lennemann NJ, Sinn PL, et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A. 2011;108(20):8426–8431. doi:10.1073/pnas.1019030108
   PubMed Web of Science ®Google Scholar
• Ji X, Olinger GG, Aris S, Chen Y, Gewurz H, Spear GT. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol. 2005;86(Pt 9):2535–2542. doi:10.1099/vir.0.81199-0
   PubMed Web of Science ®Google Scholar
• Michelow IC, Lear C, Scully C, et al. High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis. 2011;203(2):175–179. doi:10.1093/infdis/jiq025
   PubMed Web of Science ®Google Scholar
• Johnson JC, Martinez O, Honko AN, Hensley LE, Olinger GG, Basler CF. Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antiviral Res. 2014;107:102–109. doi:10.1016/j.antiviral.2014.04.014
   PubMed Web of Science ®Google Scholar
• Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196(Suppl 2):S390–S399. doi:10.1086/520598
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362(9400):1953–1958. doi:10.1016/S0140-6736(03)15012-X
   PubMed Web of Science ®Google Scholar
• Wolf T, Kann G, Becker S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428–1435. doi:10.1016/S0140-6736(14)62384-9
   PubMed Web of Science ®Google Scholar
• Poliquin G, Funk D, Jones S, et al. Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model. Intensive Care Med Exp. 2019;7(1):54. doi:10.1186/s40635-019-0268-8
   Web of Science ®Google Scholar
• Zeng X, Blancett CD, Koistinen KA, et al. Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys. Nat Microbiol. 2017;2(9):17113. doi:10.1038/nmicrobiol.2017.113
   Web of Science ®Google Scholar
• Sagui E, Janvier F, Baize S, et al. Severe Ebola virus infection with encephalopathy: evidence for direct virus involvement. Clin Infect Dis. 2015;61(10):1627–1628. doi:10.1093/cid/civ606
   Web of Science ®Google Scholar
• Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388(10043):498–503. doi:10.1016/S0140-6736(16)30386-5
   PubMed Web of Science ®Google Scholar
• de Greslan T, Billhot M, Rousseau C, et al. Ebola virus-related encephalitis. Clin Infect Dis. 2016;63(8):1076–1078. doi:10.1093/cid/ciw469
   Web of Science ®Google Scholar
• Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med. 2015;372(25):2423–2427. doi:10.1056/NEJMoa1500306
   PubMed Web of Science ®Google Scholar
• Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of ebola virus disease survivors – final report. N Engl J Med. 2017;377(15):1428–1437. doi:10.1056/NEJMoa1511410
   PubMed Web of Science ®Google Scholar
• Mate SE, Kugelman JR, Nyenswah TG, et al. Molecular evidence of sexual transmission of ebola virus. N Engl J Med. 2015;373(25):2448–2454. doi:10.1056/NEJMoa1509773
   PubMed Web of Science ®Google Scholar